Cargando…

In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir

Ensitrelvir, an oral antiviral agent that targets a SARS-CoV-2 main protease (3CLpro or Nsp5), is clinically useful against SARS-CoV-2 including its omicron variants. Since most omicron subvariants have reduced sensitivity to most monoclonal antibody therapies, SARS-CoV-2 resistance to other antivir...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kiso, Maki, Yamayoshi, Seiya, Iida, Shun, Furusawa, Yuri, Hirata, Yuichiro, Uraki, Ryuta, Imai, Masaki, Suzuki, Tadaki, Kawaoka, Yoshihiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349878/ https://www.ncbi.nlm.nih.gov/pubmed/37454219 http://dx.doi.org/10.1038/s41467-023-40018-1

Ejemplares similares

In SARS-CoV-2 delta variants, Spike-P681R and D950N promote membrane fusion, Spike-P681R enhances spike cleavage, but neither substitution affects pathogenicity in hamsters
por: Furusawa, Yuri, et al.
Publicado: (2023)

In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir
por: Kiso, Maki, et al.
Publicado: (2023)

Treatment of Highly Pathogenic H7N9 Virus-Infected Mice with Baloxavir Marboxil
por: Kiso, Maki, et al.
Publicado: (2019)

Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB
por: Imai, Masaki, et al.
Publicado: (2022)

Triple combination therapy of favipiravir plus two monoclonal antibodies eradicates influenza virus from nude mice
por: Kiso, Maki, et al.
Publicado: (2020)

Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates
por: Uraki, Ryuta, et al.
Publicado: (2023)

The accuracy of reverse genetics systems for SARS‐CoV‐2: Circular polymerase extension reaction versus bacterial artificial chromosome
por: Furusawa, Yuri, et al.
Publicado: (2023)

A Broadly Reactive Human Anti-hemagglutinin Stem Monoclonal Antibody That Inhibits Influenza A Virus Particle Release
por: Yamayoshi, Seiya, et al.
Publicado: (2017)

Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1
por: Uraki, Ryuta, et al.
Publicado: (2023)

Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB
por: Uraki, Ryuta, et al.
Publicado: (2023)

Subclade 2.2.1-Specific Human Monoclonal Antibodies That Recognize an Epitope in Antigenic Site A of Influenza A(H5) Virus HA Detected between 2015 and 2018
por: Okuda, Moe, et al.
Publicado: (2019)

Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate
por: Uraki, Ryuta, et al.
Publicado: (2023)

Efficacy of Antiviral Agents against the Omicron Subvariant BA.2.75
por: Takashita, Emi, et al.
Publicado: (2022)

Antiviral efficacy against and replicative fitness of an XBB.1.9.1 clinical isolate
por: Uraki, Ryuta, et al.
Publicado: (2023)

Antibody induction and immune response in nasal cavity by third dose of SARS-CoV-2 mRNA vaccination
por: Ishizaka, Aya, et al.
Publicado: (2023)

Recurring and Adaptable Binding Motifs in Broadly Neutralizing Antibodies to Influenza Virus Are Encoded on the D3-9 Segment of the Ig Gene
por: Wu, Nicholas C., et al.
Publicado: (2018)

Enhanced Replication of Highly Pathogenic Influenza A(H7N9) Virus in Humans
por: Yamayoshi, Seiya, et al.
Publicado: (2018)

Isolation and Characterization of Human Monoclonal Antibodies That Recognize the Influenza A(H1N1)pdm09 Virus Hemagglutinin Receptor-Binding Site and Rarely Yield Escape Mutant Viruses
por: Yasuhara, Atsuhiro, et al.
Publicado: (2018)

A broadly protective human monoclonal antibody targeting the sialidase activity of influenza A and B virus neuraminidases
por: Yasuhara, Atsuhiro, et al.
Publicado: (2022)

Transmission and re-infection of Omicron variant XBB.1.5 in hamsters
por: Halfmann, Peter J., et al.
Publicado: (2023)

A 265-Nanometer High-Power Deep-UV Light-Emitting Diode Rapidly Inactivates SARS-CoV-2 Aerosols
por: Ueki, Hiroshi, et al.
Publicado: (2022)

Efficacy of antivirals and mRNA vaccination against an XBF clinical isolate
por: Uraki, Ryuta, et al.
Publicado: (2023)

Amino acids substitutions in the PB2 protein of H7N9 influenza A viruses are important for virulence in mammalian hosts
por: Yamayoshi, Seiya, et al.
Publicado: (2015)

Plasminogen activator inhibitor 1 is not a major causative factor for exacerbation in a mouse model of SARS-CoV-2 infection
por: Nakayama, Takashin, et al.
Publicado: (2023)

Evaluation of the fusion partner cell line SPYMEG for obtaining human monoclonal antibodies against influenza B virus
por: SONI, Priyanka, et al.
Publicado: (2018)

Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters
por: Takamatsu, Yuki, et al.
Publicado: (2022)

In Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6
por: Takashita, Emi, et al.
Publicado: (2022)

Foxp3(+) CD4(+) regulatory T cells control dendritic cells in inducing antigen-specific immunity to emerging SARS-CoV-2 antigens
por: Uraki, Ryuta, et al.
Publicado: (2021)

Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2
por: Kawaoka, Yoshihiro, et al.
Publicado: (2022)

Co-administration of Favipiravir and the Remdesivir Metabolite GS-441524 Effectively Reduces SARS-CoV-2 Replication in the Lungs of the Syrian Hamster Model
por: Chiba, Shiho, et al.
Publicado: (2022)

Strain-Specific Contribution of Eukaryotic Elongation Factor 1 Gamma to the Translation of Influenza A Virus Proteins
por: Sammaibashi, Shuhei, et al.
Publicado: (2018)

Identification of Amino Acid Residues in Influenza A Virus PA-X That Contribute to Enhanced Shutoff Activity
por: Oishi, Kohei, et al.
Publicado: (2019)

Protective efficacy of orally administered, heat-killed Lactobacillus pentosus b240 against influenza A virus
por: Kiso, Maki, et al.
Publicado: (2013)

Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo
por: Kuroda, Takayuki, et al.
Publicado: (2023)

Sensitivity of Commercially Available Influenza Rapid Diagnostic Tests in the 2018–2019 Influenza Season
por: Sakai-Tagawa, Yuko, et al.
Publicado: (2019)

G Protein Pathway Suppressor 1 Promotes Influenza Virus Polymerase Activity by Activating the NF-κB Signaling Pathway
por: Kuwahara, Tomoko, et al.
Publicado: (2019)

Comparative Sensitivity of Rapid Antigen Tests for the Delta Variant (B.1.617.2) of SARS-CoV-2
por: Sakai-Tagawa, Yuko, et al.
Publicado: (2021)

Effectiveness of Face Masks in Preventing Airborne Transmission of SARS-CoV-2
por: Ueki, Hiroshi, et al.
Publicado: (2020)

Identification of Novel Adjuvants for Ebola Virus-Like Particle Vaccine
por: Feng, Huapeng, et al.
Publicado: (2020)

Diversity of antigenic mutants of influenza A(H1N1)pdm09 virus escaped from human monoclonal antibodies
por: Yasuhara, Atsuhiro, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ul7l3ap25iubc99jf16godose0